Interestingly, the injection of CD8+ cultured in Th9 skewing conditions (IL-4, TGF-β, and anti-IFNγ) was shown to give rise to Tc9 with stronger anti-tumor tumor effects than IFN-γ cytolytic CD8+ T cells in pre-clinical cancer models [133]. The gene discussed is CD8A; the disease is neoplasm.